Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Oral anti-coagulant given green light for use in Scotland

  • Comment
The first oral antico-agulant to be licensed in the UK for more than 50 years has been approved for routine use in the NHS in Scotland

Dabigatran etexilate (Pradaxa), manufactured by Boehringer Ingelheim, has been accepted by the Scottish Medicines Consortium for the primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.

It is administered as a fixed, oral dose and does not require anti-coagulation monitoring.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs